Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
-
- STATUS
- Not Recruiting
-
- End date
- Jan 22, 2027
-
- participants needed
- 525
-
- sponsor
- Merck Sharp & Dohme LLC
Toll Free Number
Primary Contact
Poudre Valley Health System ( Site 1402) (8.1 mi away) Contact
+104 other locationSummary
This is an efficacy and safety study of olaparib alone or in combination with bevacizumab being compared to bevacizumab with a fluoropyrimidine in participants with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. The primary hypotheses are: Olaparib + Bevacizumab is superior to a fluoropyrimidine + Bevacizumab with respect to progression-free survival (PFS) using Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR); Olaparib is superior to a fluoropyrimidine + Bevacizumab with respect to PFS using RECIST 1.1 as assessed by BICR.
Details
| Condition | Metastatic Colorectal Cancer |
|---|---|
| Treatment | Capecitabine, bevacizumab, 5-FU, olaparib, Leucovorin/ levoleucovorin |
| Clinical Study Identifier | NCT04456699 |
| Sponsor | Merck Sharp & Dohme LLC |
| Last Modified on | 8 August 2022 |
Similar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer